When FDA deployed the “fatal flaw” concept during ENDS PMTA reviews, it was seen by many as a...
FDA’s Acknowledgement of Harm Reduction Marks a Turning Point at FDLI 2025
The 2025 Food and Drug Law Institute (FDLI) Tobacco and Nicotine Conference delivered something the industry has been waiting for: a visible and vocal presence from the FDA’s Center for Tobacco Products (CTP), and most significantly, an explicit...
All articles
The 2025 CORESTA Product Science and Product Technology (PSPT) Conference brought together...
The 2025 Global Tobacco and Nicotine Forum (GTNF), held in Brussels, brought together policymakers,...
By Paul Hardman, Chemistry Consultant at Broughton With expert regulatory commentary from Lilian...
As the U.S. Food and Drug Administration’s Center for Tobacco Products (CTP) adjusts to a new era...
As the U.S. Food and Drug Administration (FDA) seeks to modernise its regulatory processes,...
Since January 2025, the regulatory landscape for tobacco and nicotine products in the United States...
Broughton has been engaged in collaborative discussions with the European Directorate for the...
When developing a nicotine product, the choice between freebase nicotine and nicotine salts plays a...
If you have a specific question for one of our scientific or regulatory experts, get in touch with a member of our team today.
